- Home
- MOBX vs KLRS Comparison
MOBX vs KLRS Comparison
Compare MOBX & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- KLRS
- Stock Information
- Founded
- MOBX 2020
- KLRS 2019
- Country
- MOBX United States
- KLRS United States
- Employees
- MOBX N/A
- KLRS N/A
- Industry
- MOBX
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOBX
- KLRS Health Care
- Exchange
- MOBX Nasdaq
- KLRS Nasdaq
- Market Cap
- MOBX 52.0M
- KLRS 46.0M
- IPO Year
- MOBX N/A
- KLRS N/A
- Fundamental
- Price
- MOBX $0.47
- KLRS $6.31
- Analyst Decision
- MOBX
- KLRS Strong Buy
- Analyst Count
- MOBX 0
- KLRS 3
- Target Price
- MOBX N/A
- KLRS $21.50
- AVG Volume (30 Days)
- MOBX 1.8M
- KLRS 147.9K
- Earning Date
- MOBX 12-18-2025
- KLRS 11-12-2025
- Dividend Yield
- MOBX N/A
- KLRS N/A
- EPS Growth
- MOBX N/A
- KLRS N/A
- EPS
- MOBX N/A
- KLRS N/A
- Revenue
- MOBX $10,984,000.00
- KLRS N/A
- Revenue This Year
- MOBX N/A
- KLRS N/A
- Revenue Next Year
- MOBX N/A
- KLRS N/A
- P/E Ratio
- MOBX N/A
- KLRS N/A
- Revenue Growth
- MOBX 180.13
- KLRS N/A
- 52 Week Low
- MOBX $0.40
- KLRS $2.14
- 52 Week High
- MOBX $2.47
- KLRS $12.90
- Technical
- Relative Strength Index (RSI)
- MOBX 32.53
- KLRS 57.79
- Support Level
- MOBX $0.43
- KLRS $6.04
- Resistance Level
- MOBX $0.47
- KLRS $7.07
- Average True Range (ATR)
- MOBX 0.06
- KLRS 0.66
- MACD
- MOBX -0.00
- KLRS 0.08
- Stochastic Oscillator
- MOBX 18.40
- KLRS 64.94
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.